股本结构
单位：万股
| 公告日期 | 2024-04-25 | 2024-02-29 | 2024-02-29 | 2023-11-02 | 2023-11-02 | 2023-08-09 |
|---|---|---|---|---|---|---|
| 证券总股本 | 4471.04 | 4467.72 | 4467.70 | 4467.72 | 4467.70 | 4467.72 |
| 普通股本 | 4471.04 | 4467.72 | 4467.70 | 4467.72 | 4467.70 | 4467.72 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 6.06 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-04-22 | 2024-02-22 | 2023-12-31 | 2023-10-26 | 2023-09-30 | 2023-08-03 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-25 | 4471.04 | 未披露 | 定期报告 | 2024-04-22 |
| 2024-02-29 | 4467.72 | 未披露 | 定期报告 | 2024-02-22 |
| 2024-02-29 | 4467.70 | 未披露 | 定期报告 | 2023-12-31 |
| 2023-11-02 | 4467.72 | 未披露 | 定期报告 | 2023-10-26 |
| 2023-11-02 | 4467.70 | 6.06 | 定期报告 | 2023-09-30 |
| 2023-08-09 | 4467.72 | 未披露 | 定期报告 | 2023-08-03 |
| 2023-08-09 | 4467.70 | 未披露 | 定期报告 | 2023-06-30 |
| 2023-05-04 | 4467.72 | 未披露 | 定期报告 | 2023-04-27 |
| 2023-05-04 | 4467.70 | 未披露 | 定期报告 | 2023-03-31 |
| 2023-03-02 | 4467.72 | 未披露 | 定期报告 | 2023-02-23 |
| 2023-03-02 | 4467.70 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon conversion of Series E Convertible Preferred Stock
|
2022-12-31 |
| 2022-11-03 | 4467.72 | 未披露 | 定期报告 | 2022-10-27 |
| 2022-11-03 | 4333.50 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of stock options
|
2022-09-30 |
| 2022-08-04 | 4333.49 | 未披露 | 定期报告 | 2022-07-28 |
| 2022-08-04 | 4330.60 | 未披露 | 定期报告 | 2022-06-30 |
| 2022-05-05 | 4330.61 | 未披露 | 定期报告 | 2022-04-28 |
| 2022-05-05 | 4330.60 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Issuance of common stock upon conversion of Series E Convertible Preferred Stock
|
2022-03-31 |
| 2022-02-24 | 4330.61 | 未披露 | 定期报告 | 2022-02-17 |
| 2022-02-24 | 4196.40 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock upon exercise of warrants
Sale of common stock, net of expenses
|
2021-12-31 |
| 2021-11-18 | 4196.37 | 未披露 |
更多>>
1.Securities being offered 2,411,575 shares.
2.All information in this prospectus supplement is based on 39,552,129 shares of common stock outstanding as of September 30, 2021.
|
2021-11-18 |
| 2021-08-05 | 3955.21 | 未披露 | 定期报告 | 2021-07-30 |
| 2021-08-05 | 3955.20 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Sale of common stock, net of expenses
|
2021-06-30 |
| 2021-05-06 | 3755.21 | 未披露 | 定期报告 | 2021-04-29 |
| 2021-05-06 | 3755.20 | 未披露 |
更多>>
From January 1, 2021 to March 31, 2021
Issuance of common stock upon exercise of warrants
|
2021-03-31 |
| 2021-03-12 | 3755.21 | 71.56 | 定期报告 | 2021-03-11 |
| 2021-02-25 | 3705.21 | 未披露 | 定期报告 | 2021-02-18 |
| 2021-02-25 | 3678.08 | 71.56 |
更多>>
From December 31, 2019 to December 31, 2020
Sale of common stock, preferred stock and warrants, net of expenses
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment
Issuance of common stock upon conversion of Series D Convertible Preferred Stock
Issuance of common stock upon conversion of Series E Convertible Preferred Stock
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon exercise of stock options
Common Stock par value adjustment
|
2020-12-31 |
| 2020-11-05 | 3532.46 | 未披露 | 定期报告 | 2020-10-30 |
| 2020-10-02 | 3017.59 | 未披露 |
更多>>
1.Common stock offered by the company 6,500,000 shares.
2.Unless the company indicate otherwise, all information in this prospectus supplement is based on 23,675,945 shares of common stock outstanding as of August 31, 2020.
|
2020-10-02 |
| 2020-11-05 | 2628.57 | 92.64 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of warrants
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock units
|
2020-09-30 |
| 2020-09-29 | 2367.59 | 未披露 | 定期报告 | 2020-08-31 |
| 2020-08-11 | 2322.79 | 未披露 | 定期报告 | 2020-08-06 |
| 2020-08-11 | 2132.51 | 92.64 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment
Sale of common stock, preferred stock and warrants
Issuance of common stock upon conversion of Series D Convertible Preferred Stock
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
|
2020-06-30 |
| 2020-06-26 | 1996.81 | 106.20 | 定期报告 | 2020-06-25 |
| 2020-06-17 | 1923.90 | 未披露 |
更多>>
1.Securities being offered 1,984,328 Shares to the Buyers
2.Unless we indicate otherwise, all information in this prospectus supplement is based on 17,254,622 shares of common stock outstanding as of June 15, 2020
|
2020-06-17 |
| 2020-06-17 | 1725.46 | 未披露 | 定期报告 | 2020-06-15 |
| 2020-05-27 | 1470.66 | 未披露 |
更多>>
1.Securities being offered 1,205,400 shares of our common stock
2.Unless we indicate otherwise, all information in this prospectus supplement is based on 13,501,222 shares of common stock outstanding as of May 26, 2020
|
2020-05-27 |
| 2020-05-22 | 1350.12 | 21.53 | 定期报告 | 2020-05-21 |
| 2020-05-07 | 1230.33 | 未披露 | 定期报告 | 2020-04-30 |
| 2020-04-10 | 1191.61 | 未披露 | 定期报告 | 2020-04-10 |
| 2020-04-10 | 1101.11 | 未披露 | 定期报告 | 2020-04-09 |
| 2020-05-07 | 1101.06 | 6.06 |
更多>>
From January 1, 2020 to March 31, 2020
Sale of common stock and warrants
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
|
2020-03-31 |
| 2020-03-04 | 1021.03 | 未披露 | 定期报告 | 2020-03-04 |
| 2020-02-27 | 1020.96 | 未披露 | 定期报告 | 2020-02-20 |
| 2020-02-27 | 859.36 | 6.06 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon conversion of Series C Convertible Preferred Stock
Issuance of common stock for share rounding as a result of reverse stock split
|
2019-12-31 |
| 2019-11-01 | 774.24 | 6.06 | 定期报告 | 2019-10-31 |
| 2019-11-07 | 643.65 | 6.06 |
更多>>
from June 30, 2019 to September 30, 2019
Sale of common stock and warrants, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
|
2019-09-30 |
| 2019-08-22 | 571.31 | 未披露 | 定期报告 | 2019-08-22 |
| 2019-08-08 | 544.58 | 未披露 | 定期报告 | 2019-07-31 |
| 2019-08-08 | 544.14 | 6.06 |
更多>>
From March 31, 2019 to June 30, 2019
Issuance of common stock upon conversion of Series C Convertible Preferred Stock
Sale of common stock and warrants, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
|
2019-06-30 |
| 2019-06-25 | 544.14 | 26.06 | 定期报告 | 2019-06-24 |
| 2019-05-07 | 524.52 | 未披露 | 定期报告 | 2019-04-30 |
| 2019-04-19 | 492.22 | 未披露 | 定期报告 | 2019-04-18 |
| 2019-05-07 | 452.54 | 26.06 |
更多>>
from January 1, 2019 to March 31, 2019
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $40,000 and $235,640, respectively
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock for share rounding as a result of reverse stock split
|
2019-03-31 |
| 2019-02-20 | 400.00 | 未披露 |
更多>>
AN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6 effective February 19, 2019 (the "effective Date"). The Company's common stock will begin trading on a split-adjusted basis when the markets open on February 20, 2019 under the existing trading symbol "TROV."and the number of outstanding common shares will be reduced from approximately 24.1 million shares to approximately 4.0 million shares.
|
2019-02-20 |
| 2019-02-14 | 2412.90 | 未披露 | 定期报告 | 2019-02-13 |
| 2019-03-06 | 383.19 | 6.06 |
更多>>
from December 31,2017 to December 31,2018
Sale of common stock and warrants, net of expenses
Sale of Series B Convertible Preferred Stock, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
Issuance of common stock for share rounding as a result of reverse stock split
|
2018-12-31 |
| 2018-12-18 | 2299.12 | 未披露 | 定期报告 | 2018-12-14 |
| 2018-11-07 | 2299.09 | 未披露 | 定期报告 | 2018-10-31 |
| 2018-11-07 | 2295.72 | 6.06 |
更多>>
from January 1, 2018 to September 30, 2018
Sale of Series B Convertible Preferred Stock, net of expenses
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
Sale of common stock and warrants, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock for share rounding as a result of reverse stock split
|
2018-09-30 |
| 2018-08-03 | 1768.88 | 未披露 | 定期报告 | 2018-07-31 |
| 2018-08-03 | 1730.50 | 6.63 |
更多>>
from January 1, 2018 to June 30, 2018
Sale of Series B Convertible Preferred Stock, net of expenses
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
Issuance of common stock upon exercise of warrants
Sale of common stock and warrants, net of expenses
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock for share rounding as a result of reverse stock split
|
2018-06-30 |
| 2018-06-04 | 490.00 | 未披露 |
更多>>
As a result of the reverse split, each 12 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 59.4 million shares to approximately 4.9 million shares. Proportionate adjustments will be made to the conversion and exercise prices of the company's outstanding warrants, stock options, and to the number of shares issued and issuable under the company's equity incentive plans. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the par value of the common stock.
|
2018-06-04 |
| 2018-04-27 | 5937.82 | 未披露 | 定期报告 | 2018-04-26 |
| 2018-05-08 | 5883.30 | 6.06 |
更多>>
from January 1, 2018 to March 31, 2018
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
|
2018-03-31 |
| 2018-02-26 | 5529.02 | 未披露 | 定期报告 | 2018-02-12 |
| 2018-02-26 | 5279.16 | 6.06 |
更多>>
from December 31, 2016 to December 31, 2017
Sale of common stock, net of expenses
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon vesting of restricted stock awards
|
2017-12-31 |
| 2017-12-12 | 3810.55 | 未披露 | 定期报告 | 2017-12-11 |
| 2017-11-09 | 3810.65 | 未披露 | 定期报告 | 2017-10-31 |
| 2017-11-09 | 3810.53 | 6.06 | 定期报告 | 2017-09-30 |
| 2017-09-29 | 3810.55 | 未披露 | 定期报告 | 2017-09-28 |
| 2017-08-09 | 3726.96 | 未披露 | 定期报告 | 2017-07-31 |
| 2017-08-09 | 3107.69 | 6.06 | 定期报告 | 2017-06-30 |
| 2017-04-28 | 3097.30 | 未披露 | 定期报告 | 2017-04-24 |
| 2017-05-10 | 3096.78 | 6.06 | 定期报告 | 2017-03-31 |
| 2017-03-15 | 3096.50 | 未披露 | 定期报告 | 2017-02-28 |
| 2017-03-15 | 3069.68 | 6.06 |
更多>>
from December 31, 2015 to December 31, 2016
Sale of common stock, net of expenses
Issuance of common stock upon exercise of stock options
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
|
2016-12-31 |
| 2016-11-09 | 3061.54 | 未披露 | 定期报告 | 2016-10-31 |
| 2016-11-09 | 3059.91 | 6.06 | 定期报告 | 2016-09-30 |
| 2016-08-04 | 3014.75 | 未披露 | 定期报告 | 2016-07-31 |
| 2016-08-04 | 3014.73 | 6.06 | 定期报告 | 2016-06-30 |
| 2016-05-10 | 2986.18 | 未披露 | 定期报告 | 2016-04-29 |
| 2016-05-10 | 2978.26 | 6.06 | 定期报告 | 2016-03-31 |
| 2016-03-31 | 2978.28 | 未披露 | 定期报告 | 2016-03-21 |
| 2016-03-10 | 2975.78 | 未披露 | 定期报告 | 2016-02-29 |
| 2016-03-10 | 2973.76 | 6.06 |
更多>>
from December 31, 2014 to December 31, 2015
Sale of common stock, net of expenses
Issuance of common stock upon exercise of stock options
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
|
2015-12-31 |
| 2015-10-16 | 2972.28 | 未披露 | 定期报告 | 2015-10-12 |
| 2015-11-09 | 2972.26 | 6.06 | 定期报告 | 2015-09-30 |
| 2015-08-10 | 2962.26 | 未披露 | 定期报告 | 2015-07-31 |
| 2015-08-10 | 2487.26 | 6.06 | 定期报告 | 2015-06-30 |
| 2015-05-05 | 2445.51 | 未披露 | 定期报告 | 2015-04-30 |
| 2015-04-20 | 2437.42 | 未披露 | 定期报告 | 2015-04-20 |
| 2015-05-05 | 2430.73 | 6.06 | 定期报告 | 2015-03-31 |
| 2015-03-12 | 2412.38 | 未披露 | 定期报告 | 2015-02-27 |
| 2015-03-12 | 1891.58 | 6.06 |
更多>>
From December 31,2013 to December 31,2014
Issuance of common stock upon net exercise of warrant
|
2014-12-31 |
| 2014-11-06 | 1890.28 | 6.06 | 定期报告 | 2014-09-30 |
| 2014-08-07 | 1890.28 | 6.06 | 定期报告 | 2014-06-30 |
| 2014-05-12 | 1890.30 | 未披露 | 定期报告 | 2014-05-09 |
| 2014-05-12 | 1890.28 | 6.06 | 定期报告 | 2014-03-31 |
| 2014-03-17 | 1890.30 | 未披露 | 定期报告 | 2014-03-13 |
| 2014-03-17 | 1890.28 | 6.06 |
更多>>
from December 31, 2012 to December 31, 2013
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
Issuance of common stock upon net exercise of stock options
Issuance of common stock upon exercise of stock options
|
2013-12-31 |
| 2013-11-14 | 1890.30 | 未披露 | 定期报告 | 2013-11-08 |
| 2013-11-14 | 1889.19 | 6.06 |
更多>>
from December 31, 2012 to September 30, 2013
Issuance of common stock upon conversion of preferred stock
Sale of common stock, net of expenses
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
Issuance of common stock upon net exercise of stock option
|
2013-09-30 |
| 2013-08-14 | 1884.63 | 未披露 | 定期报告 | 2013-08-09 |
| 2013-08-14 | 1572.95 | 7.81 |
更多>>
from December 31, 2012 to June 30, 2013
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
|
2013-06-30 |
| 2013-05-14 | 1561.64 | 未披露 | 定期报告 | 2013-05-09 |
| 2013-05-14 | 1551.62 | 7.81 |
更多>>
from December 31,2012 to March 31,2013
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
|
2013-03-31 |
| 2013-04-01 | 1560.39 | 未披露 | 定期报告 | 2013-03-22 |
| 2013-04-01 | 1547.82 | 9.56 |
更多>>
from December 31, 2011 to December 31, 2012
Units issued via registered underwritten direct public offering and private placement of units
Issuance of common stock and warrant to shareholder as finder’s fees
Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.
Issuance of common stock in connection with consulting services
Issuance of common stock upon exercise of stock options
Issuance of common stock upon net exercise of warrant
|
2012-12-31 |
| 2012-10-18 | 1418.09 | 9.56 | 定期报告 | 2012-10-16 |
| 2012-11-14 | 1418.07 | 9.56 |
更多>>
from December 31, 2011 to September 30, 2012
Units issued via registered direct public offering and private placement of units
Issuance of common stock and warrant to shareholder as finder’s fees
Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.
Issuance of common stock in connection with consulting services
|
2012-09-30 |
| 2012-08-14 | 1417.81 | 未披露 | 定期报告 | 2012-08-09 |
| 2012-08-14 | 1417.51 | 9.56 |
更多>>
from December 31, 2011 to June 30, 2012
Units issued via registered direct public offering and private placement of units
Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.
Issuance of common stock in connection with consulting services
|
2012-06-30 |
| 2012-05-30 | 1383.01 | 未披露 | 定期报告 | 2012-05-29 |
From December 31, 2021 to December 31, 2022
Issuance of common stock upon exercise of stock options
Issuance of common stock upon conversion of Series E Convertible Preferred Stock
From June 30, 2022 to September 30, 2022
Issuance of common stock upon exercise of stock options
From January 1, 2022 to March 31, 2022
Issuance of common stock upon conversion of Series E Convertible Preferred Stock
From December 31, 2020 to December 31, 2021
Issuance of common stock upon exercise of warrants
Sale of common stock, net of expenses
1.Securities being offered 2,411,575 shares.
2.All information in this prospectus supplement is based on 39,552,129 shares of common stock outstanding as of September 30, 2021.
From March 31, 2021 to June 30, 2021
Sale of common stock, net of expenses
From January 1, 2021 to March 31, 2021
Issuance of common stock upon exercise of warrants
From December 31, 2019 to December 31, 2020
Sale of common stock, preferred stock and warrants, net of expenses
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment
Issuance of common stock upon conversion of Series D Convertible Preferred Stock
Issuance of common stock upon conversion of Series E Convertible Preferred Stock
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon exercise of stock options
Common Stock par value adjustment
1.Common stock offered by the company 6,500,000 shares.
2.Unless the company indicate otherwise, all information in this prospectus supplement is based on 23,675,945 shares of common stock outstanding as of August 31, 2020.
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of warrants
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock units
From March 31, 2020 to June 30, 2020
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment
Sale of common stock, preferred stock and warrants
Issuance of common stock upon conversion of Series D Convertible Preferred Stock
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
1.Securities being offered 1,984,328 Shares to the Buyers
2.Unless we indicate otherwise, all information in this prospectus supplement is based on 17,254,622 shares of common stock outstanding as of June 15, 2020
1.Securities being offered 1,205,400 shares of our common stock
2.Unless we indicate otherwise, all information in this prospectus supplement is based on 13,501,222 shares of common stock outstanding as of May 26, 2020
From January 1, 2020 to March 31, 2020
Sale of common stock and warrants
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
from December 31, 2018 to December 31, 2019
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon conversion of Series C Convertible Preferred Stock
Issuance of common stock for share rounding as a result of reverse stock split
from June 30, 2019 to September 30, 2019
Sale of common stock and warrants, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
From March 31, 2019 to June 30, 2019
Issuance of common stock upon conversion of Series C Convertible Preferred Stock
Sale of common stock and warrants, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
from January 1, 2019 to March 31, 2019
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $40,000 and $235,640, respectively
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock for share rounding as a result of reverse stock split
AN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6 effective February 19, 2019 (the "effective Date"). The Company's common stock will begin trading on a split-adjusted basis when the markets open on February 20, 2019 under the existing trading symbol "TROV."and the number of outstanding common shares will be reduced from approximately 24.1 million shares to approximately 4.0 million shares.
from December 31,2017 to December 31,2018
Sale of common stock and warrants, net of expenses
Sale of Series B Convertible Preferred Stock, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
Issuance of common stock for share rounding as a result of reverse stock split
from January 1, 2018 to September 30, 2018
Sale of Series B Convertible Preferred Stock, net of expenses
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
Sale of common stock and warrants, net of expenses
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock for share rounding as a result of reverse stock split
from January 1, 2018 to June 30, 2018
Sale of Series B Convertible Preferred Stock, net of expenses
Issuance of common stock upon conversion of Series B Convertible Preferred Stock
Issuance of common stock upon exercise of warrants
Sale of common stock and warrants, net of expenses
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock for share rounding as a result of reverse stock split
As a result of the reverse split, each 12 pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 59.4 million shares to approximately 4.9 million shares. Proportionate adjustments will be made to the conversion and exercise prices of the company's outstanding warrants, stock options, and to the number of shares issued and issuable under the company's equity incentive plans. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the par value of the common stock.
from January 1, 2018 to March 31, 2018
Issuance of common stock upon exercise of warrants
Issuance of common stock upon vesting of restricted stock units
from December 31, 2016 to December 31, 2017
Sale of common stock, net of expenses
Issuance of common stock upon vesting of restricted stock units
Issuance of common stock upon vesting of restricted stock awards
from December 31, 2015 to December 31, 2016
Sale of common stock, net of expenses
Issuance of common stock upon exercise of stock options
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
from December 31, 2014 to December 31, 2015
Sale of common stock, net of expenses
Issuance of common stock upon exercise of stock options
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
From December 31,2013 to December 31,2014
Issuance of common stock upon net exercise of warrant
from December 31, 2012 to December 31, 2013
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
Issuance of common stock upon net exercise of stock options
Issuance of common stock upon exercise of stock options
from December 31, 2012 to September 30, 2013
Issuance of common stock upon conversion of preferred stock
Sale of common stock, net of expenses
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
Issuance of common stock upon net exercise of stock option
from December 31, 2012 to June 30, 2013
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
from December 31,2012 to March 31,2013
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon net exercise of warrant
Issuance of common stock upon exercise of warrants
from December 31, 2011 to December 31, 2012
Units issued via registered underwritten direct public offering and private placement of units
Issuance of common stock and warrant to shareholder as finder’s fees
Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.
Issuance of common stock in connection with consulting services
Issuance of common stock upon exercise of stock options
Issuance of common stock upon net exercise of warrant
from December 31, 2011 to September 30, 2012
Units issued via registered direct public offering and private placement of units
Issuance of common stock and warrant to shareholder as finder’s fees
Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.
Issuance of common stock in connection with consulting services
from December 31, 2011 to June 30, 2012
Units issued via registered direct public offering and private placement of units
Issuance of common stock in connection with Asset Purchase Agreement with MultiGen Diagnostics, Inc.
Issuance of common stock in connection with consulting services